Charles River Laboratories International (CRL) has seen several business updates lately that point to compelling market trends. CRL's stock rating was raised by Ciitgroup and Redburn raised it's target to $188. Recently, CRL has diversified its
monkey business to operate amidst political headwinds. A stock purchase by the Charles River Laboratories International chairman indicates confidence in the company's future. The company has also updated its
2025 guidance, following its Q4 2024 Earnings Call. Imperial Capital targeted CRL shares at $175, reflecting market volatility, yet showing potential growth. CRL's
collaborations with Deciphex, Singapore General Hospital, Akron Bio, CEBINA aim to innovate and expedite development in
drug and
therapeutics. Innovative product launches include the
Global Biotech Incubator Program and Apollo™ Ecosystem. Conversely, CRL has faced criticism, such as the downscaling of jobs, debt accumulation and 2021's Q4 profit fall, creating a mix of factors to consider in investment decisions.
Charles River Laboratories International CRL News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Thu, 06 Mar 2025 09:57:51 GMT -
Rating 0
- Innovation -2
- Information 8
- Rumor -5
